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ABSTRACT 
Background: Stimulant drugs are the most commonly used treatments for 
attention-deficit/hyperactivity disorder (ADHD), although the mechanism of 
action of these drugs is still not entirely understood. 
Objective: The aim of this study was to investigate he effects of the psycho- 
stimulant drug methylphenidate (MPH) on regional cerebral blood flow (rCBF), 
electrical activity of the brain, and clinical symptoms in children with ADHD 
using single-photon emission computed tomography (SPECT), electroencepha- 
lography (EEG), and neuropsychological tests. 
Methods: In this prospective cohort study, pediatric outpatients received 
MPH for 3 months at a mean dose of 1 mg/kg ° d (range, 0.5-1.5 mg/kg • d). They 
were then administered the Wechsler Intelligence Scale for Children-Revised, 
the Bender Visual-Motor Gestalt Test (BGT), EEG, and SPECT of the brain. The 
parents and/or teacher of each child were asked to complete the Conners' 
Parent Rating Scale (CPRS), the Conners' Teacher Rating Scale (CTRS), and 
the Turgay Diagnostic and Statistical Manual of Mental Disorders Fourth 
Edition-based Child and Adolescent Behavior Disorders Screening and Rating 
Scale (T-DSM-IV-S). All of the evaluations were performed at baseline and after 
3 months of MPH treatment. Each child underwent a Stroop test as an activa- 
tion method 15 minutes before the SPECT procedure. 
Results: Sixty patients were assessed for inclusion. Twenty-one children 
(18 boys [85.7%], 3 girls [14.3%]; mean [SD] age, 9.7 [1.7] years; range, 8-13 years) 
with a diagnosis of ADHD were included in and completed the study. Mean 
(SD) BGT scores before MPH treatment compared with after MPH treatment 
were significantly decreased (9.8 [4.2] vs 6.3 [3.4]; Z = -3.27; P = 0.001). After 
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treatment with MPH, the visual SPECT results suggested that low rCBF was 
normalized in the right frontotemporal reas in 10 children with ADHD. After 
treatment,  12 patients (57.1%) had no change in EEG activity, 5 (23.8%) had 
improvement, and 4 (19.0%) had worsening activity. Patients who had improve- 
ment or no worsening on EEG after MPH t reatment  were associated with 
significant improvement after MPH treatment compared with before treat- 
ment in mean (SD) CTRS scores (25.9 [14.3] vs 35.0 [14.4]; P = 0.003), teachers'  
T-DSM-IV-S total score (25.1 [14.2] vs 38.4 [18.7]; P = 0.005), and CPRS scores 
(mothers cores: 29.7 [16.6] vs 42.6 [17.2], P = 0.002; fathers' scores: 29.4 [16.8] vs 
41.9 [23.7], P = 0.004). No significant difference was found in these scores in the 
patients whose EEG findings showed deterioration after MPH treatment. The 
quantitative values for SPECT observed before treatment compared with those 
observed after 3 months of MPH treatment were not found to be significantly 
different in any areas of the brain. 
Conclusions: MPH use over 3 months was associated with improvement from 
baseline in visual-motor function and behavioral disorders in these children and 
adolescents with ADHD. However, no significant difference in rCBF or electrical 
activity in the brain was observed in this small study. (Curt Ther Res Clin Exp. 
2007;68:432-449) Copyright © 2007 Excerpta Medica, Inc. 
Key words: attention-deficit /hyperactivity disorder, single-photon emission 
computed tomography, electroencephalography, methylphenidate. 
INTRODUCTION 
Attention-deficit /hyperactivity d sorder (ADHD), which is a neuropsychiatr ic 
disorder that begins before 7 years of age, affects 3% to 5% of school-aged 
children and plays an important role in disorders of social, emotional, and 
cognitive development. 1 ADHD demonstrates itself through the core symptoms 
of attention deficiency, hyperactivity, and impulsivity. 2 For >50 years, psycho- 
stimulant drugs have been used to treat these core symptoms. Clinical and 
experimental  studies with placebo controls have demonstrated that -80% of 
patients with ADHD made significant clinical recovery with psychost imulant 
therapy. 3,4 The mechanisms of action of these stimulants in the treatment of 
ADHD, including their neurophysiologic effects, as well as associated adverse 
events (AEs), remain topics for research. 5,6 
Methylphenidate (MPH) is an effective short-term psychost imulant with a 
2- to 3-hour tl/2, the effects of which last -1 to 4 hours after administration. 
Although the mechanism of action of MPH is not well-known, it is believed 
that among the neurotransmitters in the frontostriatal areas of the brain, it 
especial ly affects the reuptake and release of dopamine. 7 MPH is thought to 
increase the degree of attention control in children with ADHD and to decrease 
the behaviors of opposing and excessive activity by maintaining the increased 
dopamine level. 4,7 In a study 8 of the effect of MPH treatment on the academic 
success of children with ADHD, their performance in mathematics improved 
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significantly due to improvement in executive functioning and working mem- 
ory. In studies 9,1° of the effects of MPH on the success of children with ADHD 
on neuropsychological  tests, improvement was observed in various areas of 
executive functioning (eg, spatial working memory, set shifting, cognitive elas- 
ticity, and planning). In children with ADHD who had been receiving long-term 
stimulant reatment, significant declines were found in mistake scores on neu- 
ropsychological tests caused by impulsivity and lack of attention. 11
Brain imaging techniques have been used in ADHD research since the late 
1980S. 12'13 Converging evidence from structural  and functional imaging studies 
implicates abnormalit ies in the frontostriatal network as the likely cause of 
ADHD. 14 A functional imaging study 15 reported hypoperfusion in the frontal 
lobe and str iatum and hyperperfusion i  the somatosensory  cortex and occipi- 
tal cortex in the baseline condition. Abnormal activation patterns during men- 
tal tasks have also been found. 16 Abnormal asymmetry,  especial ly dysfunction 
of the right prefrontal region within the frontostriatal network, has been impli- 
cated in hyperact iv i ty and inattentiveness. 17,18 Imaging studies 19,2° investigat- 
ing differences in regional cerebral blood flow (rCBF) levels before and after 
oral MPH t reatment  in chi ldren with ADHD have been repor ted  only rarely. 
In a study by Kim et al, 19 the left and right prefrontal areas, and caudate and 
thalamic areas showed significant increases in rCBF after MPH treatment. In the 
study by Lee et al, 2° MPH treatment also resulted in rCBF increase in the superior 
prefrontal area and reduction in ventral higher visual areas bilaterally. 
In an attempt o better understand the actions of stimulant medications in 
children with ADHD, the changes in e lectroencephalography (EEG) due to the 
administration of stimulants have been investigated. Chabot et a121 found that 
56.9% of 130 children with ADHD showed normalization of EEG activity after 
the administration of a stimulant, 33.8% showed no change, and 9.3% showed 
an increase in EEG abnormalit ies. Behavioral improvement after st imulant 
t reatment was seen in 81.5% of the children with ADHD and 44.7% of the child- 
ren with attention-deficit disorder, with the degree of correspondence b tween 
behavioral and quantitative EEG changes at 78.5%. Pretreatment clinical and 
quantitative EEG features could predict t reatment response with a sensitivity 
of 83.1% and a specificity of 88.2%. Swartwood et a122 and Lubar et a123 investi- 
gated the effects of MPH in 23 boys with ADHD, but did not identify any global 
changes in EEG activity associated with treatment.  In another study in children 
with ADHD who had a positive reaction to stimulant reatment,  an increase in 
beta activity in the frontal areas, a decrease in theta and alpha waves, and a 
significant correlation between changes in beta activities and improvement on 
neuropsychological  tests were reported. Another study examined EEG chan- 
ges associated with a double-blind, placebo-control led a ministration of MPH 
among 10 children, ages 8 to 13, with a pr imary diagnosis of ADHD. As a result 
of this study, an increase in beta activity in the frontal areas, a decrease in theta 
and alpha waves, a significant correlation between changes in beta activities, 
and improvement on neuropsychological  tests in children who had a positive 
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reaction to stimulant treatment, were reported (P < 0.05). 24 However, a limitation of 
that study was that the population comprised only 10 patients with ADHD. 
The aim of the present study was to examine MPH-induced changes in rCBF, 
electrical activity of the brain, and clinical symptoms in children with ADHD 
to determine the site of action of MPH using single-photon emission computed 
tomography (SPECT), EEG, and neuropsychological tests. 
PATIENTS AND METHODS 
Patients 
In this prospective cohort study, the study participants were selected 
from among children who applied to the Child and Adolescent Psychiatry 
Department outpatient clinic at the Kocaeli University School of Medicine, 
Kocaeli, Turkey. Prior to the study, its nature and purpose were fully explained 
to the patients and their parents, and written informed consent was obtained 
from each child's parent and written assent from each child for all procedures. 
The Ethics Committee of Kocaeli University approved the study protocol, 
and the study followed the principles of the Declaration of Helsinki 25 and the 
Guidline of Good Clinical Practice. 26 
At least 1 certified child psychiatrist and 1 child psychologist evaluated 
each patient. All patients included in this study received a clinical diagnosis 
of ADHD based on the Diagnostic and Statistical Manual of Mental Disorders, 
Fourth Edition (DSM-IV). 2 Children with a diagnosis of ADHD of combined sub- 
types who were right-handed (in order to prevent dominant hemisphere dif- 
ference) were eligible for the study. None of the patients had previously been 
diagnosed with ADHD, nor had they been treated with psychopharmacologic 
drugs. Patients were eligible for the study if they had an unremarkable medi- 
cal history except for ADHD. Patients were clinically screened and excluded 
for psychoses, eating disorders, substance abuse, pervasive developmental 
disorders, depression, anxiety, epilepsy, and mental retardation. Intellectual 
and learning abilities were assessed using the Turkish version of the Wechsler 
Intelligence Scale for Children-Revised (WISC-R). 27 Behavioral and emotional 
problems were assessed using the Conners' Parent Rating Scale (CPRS), 28 the 
Conners' Teacher Rating Scale (CTRS), 29 and the Turgay DSM-IV-based Child 
and Adolescent Behavior Disorders Screening and Rating Scale (T-DSM-IV-S), 3° 
which have been standardized in Turkish. 
Compliance was evaluated based on reporting by the parents at the monthly 
control meetings. The patients and parents were questioned during the monthly 
clinical evaluations regarding any AEs. 
Neuropsychological Instruments 
Wechsler Intelligence Scale for Children-Revised 
The WISC-R, developed by Wechsler, 31 was adapted to Turkish with a standardi- 
zation study conducted by Savaslr, 27 which included 1639 children from 11 different 
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city centers. The WISC-R provides 3 measurements in 3 sections: (1) general intel- 
ligence score; (2) verbal intelligence score; and (3) performance intelligence score. 
Stroop Test 
Valid, reliable studies of the Stroop test 32 have been conducted in Turkey by 
Karakas. 33 The Stroop test measures the capabil ity of an individual to maintain 
attention on 1 of 2 competing stimuli by suppressing the other. It measures 
whether patients can change their existing perception of changing desires. The 
Stroop test is used to evaluate the suppression of stimuli that distract atten- 
tion (interference r sistance) and the strength to keep the response waiting for 
the inappropriate stimuli. The test consists of 5 sections in which 4 cards are 
presented in a fixed order. In the first 2 sections, the words on the cards are 
to be read. In the other 3 sections, the colors of the words or forms are to be 
named. The duration of reading rate and the number of mistakes and correc- 
tions made are recorded for each section on the Stroop standard registration 
form. Therefore, 5 different completion durations and mistake and correct ion 
scores are obtained. 34 
Bender Visual-Motor Gestalt Test 
The Bender Visual-Motor Gestalt Test (BGT) is a developmental  test used to 
measure visual motor functioning. Specifically, it measures perception of the 
visual stimulant, visual motor coordination, and integration. Koppitz 35 evalu- 
ated and interpreted the test. Norms valid for children aged 6 to 13 years were 
determined by Yalin. 36 The scoring system, which was developed by Koppitz, 
is based on the number of mistakes made. The mistakes are classified into 
4 groups--rotat ion,  merging, shape distortion, and repetition. 
T-DSM-IV-S 
The T-DSM-IV-S was developed by Turgay 37 and adapted and translated into 
Turkish by Ercan et al. 3° The T-DSM-IV-S is based on the DSM-IV diagnostic 
criteria and assesses hyperactivity- impulsivity (9 items), inattention (9 items), 
opposit ion-defiance (8 items), and conduct disorder (15 items). A severity 
estimate is assigned for each symptom on a 4-point Likert scale (0 = not at all; 
1 = just a little; 2 = quite a bit; and 3 = very  much). Subscale scores on the 
T-DSM-IV-S are calculated by summing the scores on the items in each sub- 
scale. Although validity and reliability of this scale are not validated in Turkey, 
a very  similar scale, the ADHD Rating Scale IV, has been found to have adequate 
criterion-related validity and good reliability in different cultures as determined 
by both parents and teachers. 38,39 
Conners" Parent Rating Scale 
The 48-item Turkish form of the CPRS was translated and adapted by Dereboy 
et al. 28 The 4 indices in the test are as follows: (1) hyperactivity/impulsivity; 
(2) inattention; (3) opposition/defiance; and (4) conduct disorder. In rating his 
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or her child's behavior, the parent responds to each item on a 4-point Likert 
scale (0 = never; 1 = rarely; 2 = often; and 3 = always). The reliability and valid- 
ity of the Turkish form of the CPRS in screening attention-deficit and disruptive 
behavior disorders was demonstrated by Dereboy et al. 4° 
Conners" Teacher Rating Scale 
The 28-item CTRS was developed by Goyette et a141 and was translated into 
Turkish by Sener et al. 29 The teacher ratings are scored on a 4-point Likert 
scale (0 = never; 1 = rarely; 2 = often; and 3 = always). The reliability and 
validity of the Turkish form of the CTRS in screening attention-deficit and 
disruptive behavior  disorders was demonstrated by Sener et al. Based on the 
authors'  recommendat ions,  the total score was used instead of the subscale 
scores. 
Design and Procedure 
Prior to beginning MPH treatment,  various quest ionnaires were given to the 
patients, parents, and teachers. After the patients completed the psychometr ic  
testing and before they began MPH treatment,  they underwent he first brain 
SPECT and EEG. Patients then received MPH for 3 months at a mean dosage of 
1 mg/kg • d (range, 0.5-1.5 mg/kg • d). All patients underwent repeat psycho- 
metric testing, SPECT, and EEG at the end of the 3-month treatment period. On 
the day of the second SPECT scan, MPH was administered 90 minutes before 
99mtechnetium ethyl cysteinate dimer (99n~c-ECD) was injected and an EEG was 
performed. 99mTc-ECD was injected and the Stroop test was administered as the 
activation method 30 minutes before the SPECT assessment.  
Single-Photon Emission Computed Tomography Imaging Protocol 
During the procedure, patients were placed in the supine position in a quiet 
room. All patients received an 99mTc-ECD injection in the appropriate dose 
(10-15 mCi) based on their weight under stable conditions without sedation 
while the Stroop test was being administered. SPECT was performed using a 
single-head gamma camera with a low-energy, high-resolution, parallel-hole 
collimator (Adoc Laborataries, Milpitas, California). The energy window was 
set to 140 KeV with a 15% width. Sixty-four frames were acquired in step-and- 
shoot mode, with each frame continuing for 30 seconds. The matrix size was 
128 x 128. Raw images were reconstructed using filtered black projection (Ranp 
Hamming filter cutoff frequency: 0.35; order: 5). All images were corrected for 
attenuation using the Chang method and were evaluated visually and quanti- 
tatively. 42 For the quantitative analysis of the 4-pixel-thick transaxial slices, 
circular regions of interest were drawn on both hemispheres symmetr ical ly 
from the cerebellum and the frontal, temporal, parietal, and occipital cortices. 
Quantitative values were obtained by normalizing the counts in the regions of 
interest according to the cortex, thereby calculating the difference between 
the left and right hemispheres based on the values of the right hemisphere. 
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The quantitative values obtained before treatment were compared with those 
obtained after 3 months of treatment with MPH. 
SPECT shows the dispersion of radionuclides in the body in 3 dimensions. 43
The fact that rCBF reflects regional neural activity, and therefore metabolism, 
provides the pathophysiologic basis of brain-perfusion SPECT imaging. SPECT 
provides information about the functioning of the brain that is complementary 
to the detailed structural visualization provided by radiologic methods uch as 
computed tomography and magnetic resonance imaging. 44 
Electroencephalography Imaging Technique 
Silver disc electrodes were placed on the scalp of each patient. Readings 
were done with 8 channels and a 10-20 location system for electrode place- 
ment on the scalp. The EEG lasted 20 minutes. Hyperventilation was applied 
for 3 minutes and photic stimulation was applied at 1 to 50 Hz on odd and even 
frequencies. 
EEG is the gold standard used in the examination of patients who have or 
are suspected of having seizures. 45 EEG is used to measure lectrical activity 
in the brain; waves of different frequencies and amplitudes are recorded by 
electrodes at standardized positions. 
Statistical Analysis 
Statistical analysis was performed using SPSS 10.0 for Windows (SPSS Inc., 
Chicago, Illinois). Apart from descriptive statistical methods (mean [SD]), the 
Wilcoxon signed rank test was used because the groups did not show a normal 
distribution in the comparison of binary groups variant in quantity. Differences 
in quality were compared using the Z 2 test. The results are provided within a 
95% reliability range; P < 0.05 was considered statistically significant. A power 
calculation was not done because of the small size of the study population. 
Adjustments were not done for multiple comparisons. 
RESULTS 
Sixty patients with a diagnosis of ADHD were assessed for inclusion. Twenty-one 
Turkish children (85.7% [18] boys, 14.3% [3] girls; mean [SD] age, 9.7 [1.7] years; 
range, 8-13 years) participated in and completed the study. Thirty-nine patients 
were excluded from the study because they refused to take part in SPECT evalu- 
ation, which is an invasive procedure that was scheduled to take place after 
3 months. Demographic and clinical characteristics are presented in Table I. 
Based on reporting by the parents at the monthly control meetings, none of the 
patients were noncompliant for >2 days during the follow-up period. 
Total mean (SD) score on the WISC-R for all children was 97.1 (14.1) and 
range was from 80 to 128. 
The second subcategory of the Stroop test, which measures reading rate, 
decreased significantly after MPH treatment (Z = -2.242; P < 0.05). There were 
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Table I. Baseline demographic and clinical characteristics of 
the study patients (N = 21). 
Characteristic Value 
Age, y 
Mean (SD) 9.7 (1.7) 
Range 8-13 
Sex, no. (%) 
Male 18 (85.7) 
Female 3 (14.3) 
WISC-R (total score) 
Mean (SD) 97.1 (14.1) 
Range 80-128 
Comorbidity, no. (%) 
LD 5 (23.8) 
ODD 2 (9.5) 
NE 2 (9.5) 
MPH dose, mg/kg ° d 
Mean 1 
Range 0.5-1.5 
WISC-R = Wechsler Intelligence Scale for Children-Revised; LD = learning 
disorder; ODD = opposition defiance disorder; NE = nocturnal enuresis; 
MPH = methylphenidate. 
no other significant differences observed in the other subcategories of the 
Stroop test. 
Mean (SD) BGT scores before MPH treatment compared with after MPH 
treatment were significantly decreased in the 21 study part ic ipants (9.8 [4.2] 
vs 6.3 [3.4]; Z = -3.27; P = 0.001) (Table tt). 
Compared with pretreatment scores, the mean scores on the T-DSM-IV-S 
completed by the mothers and the teachers decreased significantly after MPH 
treatment for hyperactivity/ impulsivity (12.3 [6.2] vs 7.7 [5.4], P = 0.005 and 11.4 
[6.2] vs 8.4 [6.4], P = 0.044, respectively), opposit ional defiant disorder (7.9 [4.3] 
vs 6.2 [4.9], P = 0.025 and 8.1 [5.3] vs 5.6 [4.8], P = 0.050), and total (36.5 [16.4] vs 
27.0 [17.8], P = 0.011 and 36.9 [17.2] vs 26.9 [15.4], P = 0.011). On the T-DSM-IV-S 
completed by the fathers, the scores decreased significantly for opposit ional 
defiant disorder (7.9 [5.0] vs 6.1 [4.4]; P = 0.029) and total (32.9 [16.2] vs 25.4 
[15.9]; P = 0.024), while the score for hyperactivity/ impulsivity did not change 
significantly (Table tt). 
Compared with pretreatment scores, the mean scores on the CPRS com- 
pleted by the mothers and the fathers after their children were treated with 
MPH decreased significantly (42.2 [16.1] vs 30.6 [16.1], P = 0.002 and 44.0 [21.3] 
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Table II. Findings before and after 3 months of methylphenidate treatment on the 
Turgay Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition 
(DSM-IV)-based Child and Adolescent Behavior Disorders Screening and 
Rating Scale (T-DSM-IV-S), the Conners' Parent Rating Scale (CPRS), the 
Conners' Teacher Rating Scale (CTRS), and the Bender Visual-Motor Gestalt 
Test (BGT) (N = 21). Data are given as mean (SD). 
Before After 
Psychometric Test Treatment Treatment Z* P 
Mother 
T-DSM-IV-S 
Hyperactivity/impulsivity 12.3 (6.2) 7.7 (5.4) -2.780 0.005 
Inattention 13.3 (7.1) 10.3 (6.7) -1.645 0.100 
Opposition/defiance 7.9 (4.3) 6.2 (4.9) -2.234 0.025 
Conduct disorder 2.9 (4.8) 2.2 (3.7) -1.145 0.252 
Total score 36.5 (16.4) 27.0 (17.8) -2.555 0.011 
CPRS 42.2 (16.1) 30.6 (16.1) -3.025 0.002 
Father 
T-DSM-IV-S 
Hyperactivity/impulsivity 10.7 (6.1) 7.4 (5.6) -1.925 0.054 
Inattention 12.8 (7.8) 10.1 (6.3) -1.838 0.066 
Opposition/defiance 7.9 (5.0) 6.1 (4.4) -2.179 0.029 
Conduct disorder 1.6 (2.4) 1.5 (2.7) -0.223 0.823 
Total score 32.9 (16.2) 25.4 (15.9) -2.260 0.024 
CPRS 44.0 (21.3) 29.0 (15.4) -3.304 0.001 
Teacher 
T-DSM-IV-S 
Hyperactivity/impulsivity 11.4 (6.2) 8.4 (6.4) -2.016 0.044 
Inattention 14.1 (7.7) 11.4 (6.1) -1.592 0.111 
Opposition/defiance 8.1 (5.3) 5.6 (4.8) -1.957 0.050 
Conduct disorder 3.0 (3.1) 1.3 (1.9) -1.894 0.058 
Total score 36.9 (17.2) 26.9 (15.4) -2.540 0.011 
CTRS 35.2 (13.0) 28.0 (15.9) -2.469 0.014 
BGT 9.8 (4.2) 6.3 (3.4) -3.270 0.001 
*Wilcoxon signed rank test. 
vs 29.0 [15.4], P = 0.001, respectively); the CTRS scores also decreased signifi- 
cantly (35.2 [13.0] vs 28.0 [15.9]; P = 0.014) (Table II). 
The quantitative values of SPECT observed before treatment compared 
with those observed after 3 months of MPH treatment were not found to be 
statistically significantly different in any areas of the brain. After MPH treat- 
ment, existing brain perfusion disorders became normal in 9 patients (42.9%), 
perfusion did not change in 5 patients (23.8%), normal brain perfusion became 
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disrupted in 3 patients (14.3%), and new perfusion disorders were added to the 
existing disorders in 4 patients (19.0%) (Table III). 
After 3 months of t reatment with MPH, 12 patients (57.1%) showed no change 
in EEG activity, 5 (23.8%) showed improvement, and 4 (19.0%) showed worsen- 
ing activity (Table III). 
Patients who had improvement or no worsening on EEG after MPH treatment 
improved significantly in regard to mean (SD) CTRS scores after MPH treatment 
compared with before treatment (25.9 [14.3] vs 35.0 [14.4]; P = 003) and the total 
T-DSM-IV-S scores completed by the teachers (25.1 [14.2] vs 38.4 [18.7]; P = 0.005) 
(Table IV). No significant difference was found in these scores in the patients 
whose EEG findings showed deterioration after MPH treatment (Table V). 
In the study, AEs were not monitored. However, there were no dropouts due 
to AEs. 
DISCUSSION 
Although psychost imulants are the first-line pharmacotherapy in patients with 
ADHD, their mechanism of action is not fully understood. 46The purpose of this 
study was to examine the effect of MPH treatment on rCBF, electrical activity 
of the brain, and clinical symptoms. Based on a review of the literature, this is 
one of the few studies to investigate the treatment impact of MPH by combining 
SPECT and EEG techniques. 
We examined the EEGs of children with ADHD before and after 3 months 
of t reatment with MPH. After treatment,  no changes in EEG activity were 
observed in 12 of the 21 children, improvement was observed in 5 children, and 
deterioration was observed in 4. Chabot et a121 reported that of the 130 children 
with a diagnosis of ADHD enrolled in their study, 56.9% showed improvement 
in their EEG activity, 9.3% showed disruption, and 33.8% did not show any 
change after t reatment with a stimulant. A significant decrease was found in 
BGT mistake scores after t reatment compared with before treatment in all of 
the participants. Considering that deterioration i BGT scores typical ly is more 
significant in organic brain syndromes,  recovery through treatment of electri- 
cal wave anomalies in the brain may have decreased the BGT mistake scores. 
In the present study there was a significant decrease in the scores of the 
CPRS completed by the mothers and fathers (P = 0.002 and P = 0.004, respec- 
tively), the CTRS (P = 0.003), and the T-DSM-IV-S total scores completed by the 
mothers, fathers, and teachers (P = 0.01, P = 0.03, and P = 0.005, respectively) of 
the patients whose EEG disorders showed improvement after MPH treatment. 
The decreases in the scores may indicate improvement in the clinical symp- 
toms of ADHD. Similarly, in other studies, significant improvement was found in 
the EEG activity of children with a diagnosis of ADHD who responded positively 
to stimulant reatment. 24,47 Gucuyener et a148 compared 57 children with ADHD 
and active seizures with 62 children with ADHD and EEG abnormalit ies. The 
tolerabil ity and efficacy of t reatment with antiepileptic drugs combined with 
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Table III. Electroencephalography (EEG) and single-photon emission computed 
tomography (SPECT) findings before and after 3 months of treatment 
with methylphenidate in children with attention-deficit/hyperactivity 
disorder (N = 21). 
Patient 
EEG SPECT 
Before After Before After 
Treatment Treatment Treatment Treatment 
5 
6 
7 
8 
9 
10 
11 
12 
Severe Severe Right 
paroxysmal paroxysmal temporobasal 
abnormality abnormality lobe hypoperfusion 
Normal Normal Normal perfusion 
Severe Mild Right 
paroxysmal paroxysmal temporobasal 
abnormality abnormality and bilateral frontal 
lobe hypoperfusion 
Normal Normal Right temporobasal 
lobe hypoperfusion 
Normal Normal Nonhomogeneous 
perfusion 
Normal Mild Right temporal and 
paroxysmal frontal basal lobe 
abnormality hypoperfusion 
Normal Normal Right frontal basal, 
parietal, and 
occipital lobe 
hypoperfusion 
Normal Severe Bilateral temporal 
paroxysmal and parietal lobe 
abnormality hypoperfusion 
Normal Normal Right temporal and 
frontal basal lobe 
hypoperfusion 
Normal Normal Normal perfusion 
Normal Normal Right temporobasal 
and frontal basal 
lobe hypoperfusion 
Normal Mild Normal perfusion 
paroxysmal 
abnormality 
Decreased right 
posterior parietal 
lobe perfusion, 
normalization of 
right temporobasal 
lobe perfusion 
Decreased right 
cerebellum, occipital 
cortex, tempora/Iobe, 
and frontobasal lobe 
perfusion 
Normal perfusion 
Decreased right 
cerebellum, frontobasal 
and temporobasal obe 
perfusion 
Nonhomogeneous 
perfusion 
Normal perfusion 
Normal perfusion 
Normal perfusion 
Normal perfusion 
Normal perfusion 
Normal perfusion 
Normal perfusion 
(continued) 
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Table III. (Continued) 
EEG SPECT 
Before After Before After 
Patient Treatment Treatment Treatment Treatment 
13 Severe Normal Bilateral temporal 
paroxysmal and parietal lobe 
abnormality hypoperfusion 
14 Mild Normal Normal perfusion 
paroxysmal 
abnormality 
15 Severe Moderate Normal perfusion 
paroxysmal paroxysmal 
abnormality abnormality 
16 Mild Severe Bilateral frontal lobe 
paroxysmal paroxysmal and right temporal 
abnormality abnormality lobe hypoperfusion 
17 Moderate Normal Left temporobasal 
paroxysmal lobe hypoperfusion 
abnormality 
18 Normal Normal Bilateral temporal 
and posterior parietal 
lobe hypoperfusion 
19 Normal Normal Left parietal and 
occipital lobe 
hypoperfusion 
20 Normal Normal Normal perfusion 
21 Normal Normal Right temporobasal 
lobe hypoperfusion 
Normal perfusion 
Decreased right temporal 
and frontobasal obe 
perfusion 
Normal perfusion 
Decreased left 
temporal lobe 
perfusion 
Decreased right 
frontobasal obe 
perfusion 
Normal perfusion 
Left parietal and 
occipital lobe 
hypoperfusion 
Decreased left 
temporal lobe 
perfusion 
Normal perfusion 
MPH were determined by assessing seizure frequency, changes in ADHD symp-  
toms, CPRS and CTRS scores, EEG differences, and AEs. The mean CPRS, CTRS, 
and total ADHD symptom scores at the beginning and end of the study were 
significantly different (P = 0.05, P = 0.05, and P = 0.001, respectively).  Seizure 
f requency did not change from baseline. The authors concluded that MPH was 
well-tolerated and effective in children with ADHD and concomitant  active sei- 
zures or EEG abnormalit ies.  
In the present  study, compared  with pret reatment ,  no stat ist ical ly signifi- 
cant di f ferences were found after MPH t reatment  in any of the quant i tat ive 
values in the areas  of the brain examined using SPECT. SPECT showed 9 pa- 
t ients who had decreased  rCBF before t reatment  had normal  rCBF after MPH 
treatment .  Specifically, low rCBF in the right f rontotempora l  areas became 
normal  after t reatment  with MPH. Psychost imu lants  are bel ieved to be ef- 
fect ive in the t reatment  of ADHD by increas ing per fus ion in the frontal 
regions of the brain and thereby  increasing dopamine  and noradrenal ine con- 
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Table IV. Findings before and after 3 months of methylphenidate treatment on the 
Turgay Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition 
(DSM-IV)-based Child and Adolescent Behavior Disorders Screening and 
Rating Scale (T-DSM-IV-S), the Conners' Parent Rating Scale (CPRS), the 
Conners' Teacher Rating Scale (CTRS), and the Bender Visual-Motor Gestalt 
Test (BGT) in children who improved or showed no change in electroen- 
cephalography findings after treatment (n = 17). Data are mean (SD). 
Before After 
Psychometric Test Treatment Treatment Z* P 
Mother 
T-DSM-IV-S 
Hyperactivity/impulsivity 14.0 (7.4) 9.5 (6.9) -2.16 0.03 
Inattention 11.6 (6.8) 7.1 (5.3) -2.26 0.02 
Opposition/defiance 7.7 (4.7) 6.1 (5.2) -1.77 0.07 
Conduct disorder 3.4 (5.4) 2.4 (4.2) -1.38 0.16 
Total score 36.7 (18.8) 25.8 (18.9) -2.55 0.01 
CPRS 42.7 (17.2) 29.7 (16.6) -3.10 0.002 
Father 
T-DSM-IV-S 
Hyperactivity/impulsivity 13.4 (7.9) 11.1 (6.8) -1.48 0.13 
Inattention 10.8 (6.7) 6.9 (5.9) -2.04 0.04 
Opposition/defiance 8.3 (5.6) 6.4 (4.8) -1.88 0.05 
Conduct disorder 1.7 (2.7) 1.7 (3.0) -0.07 0.91 
Total score 34.1 (17.9) 26.2 (18.1) -2.07 0.03 
CPRS 41.9 (23.7) 29.4 (16.8) -2.87 0.004 
Teacher 
T-DSM-IV-S 
Hyperactivity/impulsivity 15.4 (8.2) 11.4 (6.1) -2.24 0.02 
Inattention 11.7 (6.7) 7.8 (5.7) -2.07 0.03 
Opposition/defiance 8.5 (6.0) 4.5 (4.5) -2.61 0.009 
Conduct disorder 2.8 (3.1) 1.2 (1.9) -1.52 0.12 
Total score 38.4 (18.7) 25.1 (14.2) -2.78 0.005 
CTRS 35.0 (14.4) 25.9 (14.3) -2.92 0.003 
BGT 9.7 (4.3) 5.8 (3.0) -2.90 0.004 
*Wilcoxon signed rank test. 
centrat ions.  49Lou et a115 conducted  a s tudy  of MPH in 2 groups  of pat ients:  
6 pat ients  with ADHD alone and 13 pat ients  with ADHD in combinat ion  with 
o ther  neuro log ic  symptoms.  Inhalat ion of 133Xenon and emiss ion  tomog-  
raphy  were used in both  t reatment  groups,  as well as in a contro l  group,  
to assess  rCBF. Signif icant hypoper fus ion  was found in the r ight s t r ia tum 
in pat ients  with ADHD and in both  st r iata l  reg ions in pat ients  with ADHD 
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Table V. Findings before and after 3 months of methylphenidate treatment on the 
Turgay Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition 
(DSM-IV)-based Child and Adolescent Behavior Disorders Screening and 
Rating Scale (T-DSM-IV-S), the Conners' Parent Rating Scale (CPRS), the 
Conners' Teacher Rating Scale (CTRS), and the Bender Visual-Motor Gestalt 
Test (BGT) in children who showed deterioration in electroencephalogra- 
phy findings after 3 months of treatment (n = 4). Data are mean (SD). 
Before After 
Psychometric Test Treatment Treatment Z* P 
Mother 
T-DSM-IV-S 
Hyperactivity/impulsivity 11.4 (6.2) 12.8 (5.8) -0.542 0.5 
Inattention 14.6 (3.5) 10.0 (5.5) -1.762 0.07 
Opposition/defiance 8.8 (2.9) 6.6 (4.4) -1.604 0.1 
Conduct disorder 1.4 (1.9) 1.6 (1.8) -0.184 0.8 
Total score 36.2 (3.4) 31.0 (15.0) -0.405 0.6 
CPRS 41.0 (13.6) 33.4 (16.0) -0.674 0.5 
Father 
T-DSM-IV-S 
Hyperactivity/impulsivity 11.0 (8.0) 7.0 (3.1) -1.214 0.2 
Inattention 10.4 (4.2) 9.2 (4.6) -0.135 0.8 
Opposition/defiance 6.6 (2.6) 5.6 (3.2) -1.342 0.1 
Conduct disorder 1.2 (1.0) 1.0 (1.7) -0.272 0.7 
Total score 29.2 (9.1) 23.0 (5.5) -0.677 0.4 
CPRS 50.8 (9.8) 29.4 (10.8) -1.753 0.08 
Teacher 
T-DSM-IV-S 
Hyperactivity/impulsivity 10.2 (4.8) 11.6 (7.1) -0.135 0.8 
Inattention 10.8 (4.7) 10.4 (8.8) -0.184 0.8 
Opposition/defiance 7.0 (1.8) 9.0 (4.4) -1.461 0.1 
Conduct disorder 4.0 (3.3) 1.8 (1.7) -1.069 0.2 
Total score 32.0 (11.4) 32.8 (19.3) -0.135 0.8 
CTRS 36.0 (9.0) 35.0 (20.7) -0.135 0.8 
BGT 10.4 (4.5) 8.4 (4.1) -1.289 0.1 
*Wilcoxon signed rank test. 
and other  neuropsycho log ic  and neuro log ic  symptoms.  MPH was associated 
with increased blood flow to the striatal and poster ior  per iventr icular  regions. 
Moreover, a cardinal feature of ADHD is low striatal activity, which was par- 
tially reversible with MPH treatment.  15
In the present  study, the mean mistake score on the BGT before MPH treat- 
ment decreased significantly after t reatment  (9.8 [4.2] vs 6.3 [3.4]; P = 0.001). 
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This finding suggests that MPH has an effect that increases the attention level 
in children with ADHD. BGT measures perception of a visual stimulant, visual 
motor coordination, and integration. In a study comparing the BGT mistake 
scores, children with ADHD scored higher than those with Tourette's yn- 
drome; this situation is special to children with ADHD. 5° 
In our study, the second subsection duration of the Stroop test decreased 
significantly compared with pretreatment (Z = -2.242; P < 0.05). These findings 
demonstrate the positive effect of MPH treatment on executive functioning in 
ADHD. Our findings are similar to those of other studies. 5,51 
As discussed previously, the mean scores on the CPRS, CTRS, and T-DSM-IV-S 
all decreased significantly after treatment.  Behavioral evaluation scales con- 
tribute to both diagnosis and follow-up of a var iety of behaviors. The sensitivity 
and specificity of these scales should be proven. In this study, we used such 
scales to evaluate ADHD symptoms of children, both at home and at school, 
and with MPH treatment. The decrease in symptoms in some of the patients 
indicated apparent improvement in ADHD. Clinical and experimental  studies 
with placebo controls have found stimulant reatment to be beneficial for -80% 
of patients with ADHD. 3,4 The data obtained in our study found similarities with 
data from other studies that reported MPH treatment to be effective in improv- 
ing ADHD symptoms. 3,46 
Limitations 
This was a prospective cohort study in which the patients erved as their own 
controls. This may have introduced bias into the study, as there could have 
been changes over time that would be misclassified as being related to MPH 
treatment. In addition, patients and investigators were not blind to the fact that 
the MPH was being used. This may have led to misclassification or recall bias. 
Using SPECT, which is an invasive method, limited the number of the patients 
who agreed to take part  in the study. Although 60 patients were selected based 
on the inclusion criteria, only 21 of the patients and their parents agreed to par- 
ticipate after reading the written informed consent form. Although the sample 
size was thought o be inadequate to perform a power calculation, information 
about 21 patients may be clinically useful. Basing the evaluation of compliance 
solely on the verbal forms of parents can be considered as a significant limita- 
tion of the study. 
Throughout  he 3-month treatment period, parents were asked about the 
occurrence of AEs that might be associated with MPH in the monthly clinical 
evaluations. No patient discontinued use of the drug due to AEs. Another sig- 
nificant limitation of our study was not evaluating the AEs of each patient with 
a standard AE evaluation checklist. 
Increasing the number  of pat ients and evaluating the effects of MPH treat- 
ment on attent ion and execut ive funct ioning using more neuropsycholog ica l  
test batter ies  will contr ibute to determining the effect of MPH in chi ldren 
with ADHD. 
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CONCLUSIONS 
MPH use over 3 months was associated with improved visual-motor func- 
tion and behavioral disorders in these children and adolescents with ADHD. 
However, no significant difference in rCBF or electrical activity in the brain was 
observed in this small study. 
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